Search

Displaying results 5661 - 5670 of 10000 in total
  1. Drug

    Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB15756
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza B virus B/Washington/02/2019 live (attenuated) antigen

    go.drugbank.com/drugs/DB15758
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16705
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16723
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16725
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  7. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  8. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  9. Drug

    Clocapramine

    go.drugbank.com/drugs/DB09003
    Experimental

    Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. … In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.

  10. Drug

    Mebenil

    go.drugbank.com/drugs/DB14728
    Experimental

    An obsolete fungicide used to control various pathogens on cereals and seed potatoes.

    Synonyms: 2-Methyl-N-phenylbenzamide